Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Atara Biotherapeutics, Inc. (ATRA) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 8-K Quarterly results
Docs: "Atara Biotherapeutics Announces Second Quarter 2023 Financial Results and Operational Progress Discussions With FDA Progressing on Potential BLA Submission for Tab-cel®With Meeting Scheduled To Resolve Remaining Topic of Comparability ATA188 Phase 2 EMBOLD Study Primary Analysis and Communication Will Now Occur in Early November To Include the Last Patient Visits From More Than 90 Patients IND Cleared for Atara's First Allogeneic CAR T, ATA3219, in Relapsed/Refractory B-Cell NHL THOUSAND OAKS, Calif.—August 8, 2023—Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the second quarter 2023, ..."
05/08/2023 8-K Quarterly results
Docs: "Atara Biotherapeutics Announces First Quarter 2023 Financial Results and Operational Progress First Patients Treated in Europe with EBVALLOTM Following Transfer of EC Marketing Authorization to Pierre Fabre; Discussions with FDA Progressing ATA188 Phase 2 EMBOLD Study Primary Data Readout On-Track for October 2023 ATA3219 IND Filing Anticipated End of Q2 2023 THOUSAND OAKS, Calif.—May 8, 2023— Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the first quarter 2023, recent business highlights and key upcoming catalysts. “We are entering an important period of potential value-generat..."
02/08/2023 8-K Quarterly results
Docs: "Atara Biotherapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress Ebvallo™ EU Launch Activities Led by Pierre Fabre to Commence in Q1 2023 Discussions with FDA Progressing on Potential U.S. BLA for Tab-cel® ATA188 Phase 2 EMBOLD Study Primary Data Readout On-Track for October 2023 Cash Runway Extended into Q2 2024 THOUSAND OAKS, Calif.—February 8, 2022—Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year 2022, recent business highlights and key upcoming catalysts for 2023. “Following the landmark approval of Eb..."
11/08/2022 8-K Quarterly results
Docs: "Atara Biotherapeutics Announces Third Quarter 2022 Financial Results and Operational Progress EbvalloTM Positioned to be the First Allogeneic T-Cell Therapy Ever Approved Following CHMP Positive Opinion New ATA188 Biomarker Imaging Data Show Less Brain Atrophy and Possible Remyelination in Patients Achieving Confirmed Disability Improvement in Progressive MS Phase 1study of ATA2271 Enrollment Resumed Conference Call and Webcast Today at 1:30 p.m. PST / 4:30 p.m. EST THOUSAND OAKS, Calif.--November 8, 2022-- Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the third quarter 2022, recent business highligh..."
08/08/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
02/28/2022 8-K Quarterly results
11/04/2021 8-K Quarterly results
Docs: "Atara Biotherapeutics Announces Third Quarter 2021 Financial Results and Operational Progress Positive Pivotal Phase 3 ALLELE Data Reinforcing the Transformative Potential of Tab-cel®"
08/09/2021 8-K Quarterly results
Docs: "Atara Biotherapeutics Announces Second Quarter 2021 Financial Results and Operational Progress Progress with FDA on evaluating tab-cel ® product comparability and new robust Phase 3 ALLELE study data"
05/04/2021 8-K Quarterly results
03/01/2021 8-K Quarterly results
11/09/2020 8-K Quarterly results
Docs: "Atara Biotherapeutics Announces Third Quarter 2020 Financial Results and Operational Progress Interim Analysis of the pivotal 302 study showed tab-cel ® in EBV + PTLD achieved a 50 percent objective response rate and safety consistent with historical data"
08/05/2020 8-K Quarterly results
05/06/2020 8-K Quarterly results
02/27/2020 8-K Quarterly results
11/07/2019 8-K Quarterly results
Docs: "Atara Biotherapeutics Announces Third Quarter 2019 Financial Results and Recent Clinical, Operational and Strategic Progress"
08/08/2019 8-K Quarterly results
Docs: "Atara Biotherapeutics, Inc. Consolidated Balance Sheets June 30, December 31, 2019 2018"
05/09/2019 8-K Quarterly results
Docs: "Atara Biotherapeutics Announces First Quarter 2019 Financial Results and Recent Operational Progress"
02/26/2019 8-K Quarterly results
11/06/2018 8-K Quarterly results
Docs: "Atara Biotherapeutics Announces Third Quarter 2018 Financial Results and Recent Operational Progress"
08/01/2018 8-K Quarterly results
Docs: "Atara Biotherapeutics Announces Second Quarter 2018 Financial Results and Recent Operational Progress"
05/08/2018 8-K Quarterly results
Docs: "Atara Biotherapeutics Announces First Quarter 2018 Financial Results and Recent Operational Progress"
02/27/2018 8-K Quarterly results
Docs: "Atara Biotherapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Recent Operational Progress – Initiated two Phase 3 clinical studies to evaluate tab-cel™ in patients with Epstein-Barr virus associated post-transplant lymphoproliferative disorder who have failed rituximab and opened six MATCH and eight ALLELE study sites for enrollment in the U.S. –"
11/09/2017 8-K Quarterly results
Docs: "Atara Biotherapeutics Announces Third Quarter 2017 Financial Results and Recent Highlights"
08/07/2017 8-K Quarterly results
05/04/2017 8-K Form 8-K - Current report
03/09/2017 8-K Form 8-K - Current report
11/04/2016 8-K Quarterly results
Docs: "Atara Bio Announces Third Quarter 2016 Financial Results and Recent Highlights"
05/05/2016 8-K Form 8-K - Current report
03/03/2016 8-K Quarterly results
Docs: "Atara Bio Announces Fourth Quarter and Full Year 2015 Financial Results and Recent Highlights"
11/05/2015 8-K Quarterly results
Docs: "ATARA BIOTHERAPEUTICS ANNOUNCES THIRD QUARTER 2015 FINANCIAL RESULTS"
08/06/2015 8-K Quarterly results
Docs: "Atara Biotherapeutics Announces Second Quarter 2015 Results"
05/07/2015 8-K Quarterly results
Docs: "Atara Biotherapeutics Announces First Quarter 2015 Results"
02/26/2015 8-K Quarterly results
Docs: "Atara Biotherapeutics Announces Fourth Quarter and Full Year 2014 Operating Results"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy